Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and a plan to develop drugs for brain function and health.

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...